vai al contenuto della pagina vai al menu di navigazione
 

Patient-derived tumor xenografts: instructions for use & Improving drug development in oncology through preclinical research

XenTech’s technology is based on one of the world’s largest and best characterized collection of Patient-Derived primary tumor Xenograft models (PDX). Is a spin-off of the Institut Curie, where our scientists have conducted preclinical studies for over 15 years in collaboration with industrial and academic laboratories.

14/02/2019 dalle 14:30 alle 17:00

Dove Policlinico S. Orsola-Malpighi-Aula Murri

Contatto di riferimento

Partecipanti Dr. Stefano Cairo, Ph.D.
Head of R&D, XenTech, Evry (France)

Aggiungi l'evento al calendario